SS Innovations International (NASDAQ: SSII), a developer of surgical robotic technologies, announced that it submitted its response to a request for additional information from the U.S. Food and Drug Administration (FDA) on Oct. 5, 2026, regarding its 510(k) submission for the SSi Mantra surgical robotic system. The response includes final data from an expanded human clinical and human factors validation study, as well as a bridging study completed in August 2026 at Hospital Internacional de Colombia, a member of the Mayo Clinic Care Network. The submission covers the initial indication of cholecystectomy, or gallbladder removal. The company anticipates that the FDA will complete its review of the response and 510(k) submission in the first quarter of 2027, advancing its efforts to introduce the SSi Mantra system to the U.S. market. To view the full press release, visit https://ibn.fm/A6dJ8.
The SSi Mantra is a modular, multi-arm surgical robotic system designed to make robotic surgery more affordable and accessible. It features 3 to 5 modular robotic arms, an open-faced ergonomic surgeon command center, a large 3D 4K monitor, and a touch panel monitor for patient information. The system also includes advanced imaging capabilities, such as virtual real-time images of the robotic patient side arm carts and the ability to superimpose 3D models of diagnostic imaging. An optional tele-surgeon console, the SSi MantrAsana, offers portability and telesurgery capability. The SSi Mantra utilizes over 40 different types of robotic endo-surgical instruments to support various specialties, including cardiac surgery, and 5mm instruments for pediatric and ENT surgeries. It has been clinically validated in India in more than 190 different types of surgical procedures.
This FDA submission is a critical step for SS Innovations as it seeks to enter the U.S. market, which is dominated by established players like Intuitive Surgical. The company's focus on affordability and accessibility could disrupt the market by providing a cost-effective alternative for hospitals and surgery centers. If approved, the SSi Mantra could expand access to robotic surgery for a larger segment of the population, potentially improving patient outcomes and reducing healthcare costs. The global surgical robotics market is projected to grow significantly, and SS Innovations aims to capture a share with its innovative technology.
Headquartered in India, SS Innovations is a U.S. company focused on expanding the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions. The company's product range includes the SSi Mantra system and its comprehensive suite of SSi Mudra surgical instruments. For more information, visit ssinnovations.com or their LinkedIn page for updates. The latest news and updates relating to SSII are available in the company's newsroom at https://ibn.fm/SSII. For full terms of use and disclaimers, see https://IBN.ai/Disclaimer.
Forward-looking statements in this article involve risks and uncertainties that could cause actual results to differ materially. Undue reliance should not be placed on these statements. The company undertakes no duty to update this information unless required by law.
